Adakveo

Adakveo Infusion Therapy

Adakveo

ADAKVEO ®  (crizanlizumab-tmca) is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients, aged 16 years and older, with sickle cell disease.

Administration Information

ADAKVEO is administered by IV infusion over a period of 30 minutes at Weeks 0 and 2, then every 4 weeks.

Infusion Time
0 Min
Infusion Every 4 Weeks
0

Induction period (week 0, 2, ) - Speak With Doctor About Details

Potential Side Effects

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.

 

For a full list of potential side effects, please see the Important Safety Information and Medication Guide on the Zemaira website.

Patient Forms

Before you attend your first appointment at Omega Health, please make sure to review the documents below. The Patient Consent Form and HIPAA Privacy Authorization Form need to be filled out and signed ahead of your appointment, whereas the Notice of Privacy Practices and Patient Rights and Responsibilities are for reference only. Please contact us if you have any questions!

Patient Consent Form

Print & Sign

HIPAA Privacy Authorization Form

Print & Sign

Notice of Privacy Practice

Read

Patient Rights and Responsibilities

Read

Appointment Lateness and Cancelation

Read

The Omega Health Clinics Experience

We offer expert infusion therapy without the hassle or cost of the hospital. We employ highly trained medical staff that work with health insurance companies & physicians to provide our patients with convenient care.

At Omega Health Clinics, we’re committed to offering affordable treatment, with upfront pricing and no hidden costs. Here’s how we make it happen.